8-K: Merit Medical Acquires EndoGastric Solutions' EsophyX Z+ Device for $105 Million, Expands Endoscopy Portfolio

Merit Medical Systems has acquired the EsophyX Z+ device and related assets from EndoGastric Solutions for $105 million, aiming to expand its presence in the gastrointestinal market.

Summary

• Merit Medical Systems acquired the EsophyX Z+ device and related assets from EndoGastric Solutions for $105 million.
• The acquisition includes the device designed for minimally invasive treatment of gastroesophageal reflux disease (GERD).
• Merit financed the acquisition through borrowings under its long-term credit facility.
• The acquired assets generated approximately $26 million in revenue in the twelve months ending December 31, 2023.
• Merit expects the acquisition to contribute $13 to $15 million in revenue from the closing date through December 31, 2024.
• The acquisition is expected to be modestly dilutive to full-year 2024 non-GAAP profitability but accretive to non-GAAP gross and operating margins, non-GAAP net income, and non-GAAP EPS in the first full year post-closing.
• Merit has updated its full-year 2024 financial guidance to include the projected impact of the acquisition.
• The company reaffirmed its prior full-year 2024 financial guidance on a stand-alone basis.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the strategic acquisition and expected accretion to non-GAAP metrics, but there are some short-term dilutive effects and integration risks that temper the overall sentiment.

Positives

• The acquisition expands Merit's product portfolio in the gastrointestinal market.
• The EsophyX Z+ device offers a minimally invasive treatment option for GERD.
• The acquisition is expected to be accretive to non-GAAP gross and operating margins, non-GAAP net income, and non-GAAP EPS in the first full year post-closing.
• Merit reaffirmed its full-year 2024 financial guidance on a stand-alone basis.
• The acquisition leverages Merit's existing commercial footprint.

Negatives

• The acquisition is expected to be modestly dilutive to full-year 2024 non-GAAP profitability due to the partial-year contribution.
• The acquisition is expected to dilute Merit's full-year 2024 GAAP net income and GAAP earnings per share.
• The acquisition includes approximately $2.7 million of lower interest income on cash balances used for the purchase.
• The acquisition includes approximately $6.5 million of non-cash and non-recurring transaction-related expenses.

Risks

• The integration of the acquired assets and operations may present challenges.
• Merit's ability to achieve anticipated financial results from the acquisition is uncertain.
• There are risks associated with supply chain, manufacturing, and sterilization processes.
• Changes in economic and industry conditions could negatively impact results.
• There are risks related to managing growth through acquisitions.
• Fluctuations in interest or foreign currency exchange rates could impact results.
• There are risks associated with information technology systems, including potential security breaches.
• Governmental scrutiny and regulation of the medical device industry could impact results.
• There are risks associated with product recalls and product liability claims.
• Changes in customer purchasing patterns or the mix of products Merit sells could impact results.

Future Outlook

Merit expects the acquisition to be accretive to non-GAAP gross margin, non-GAAP operating margin, non-GAAP net income and non-GAAP earnings per share in the first full-year post close, but dilutive to Merits GAAP net income and earnings per share for that period. Merit has updated its full-year 2024 financial guidance to include the projected impact of the acquisition and reaffirmed its prior full-year 2024 financial guidance on a stand-alone basis.

Management Comments

• Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer, stated that the acquisition is consistent with their Continued Growth Initiatives and enhances their product portfolio.
• Mr. Lampropoulos also noted that the financial profile of the acquisition is compelling and expects it to be accretive to non-GAAP metrics in the first full year post-closing.

Industry Context

This acquisition reflects a trend in the medical device industry where companies are expanding their portfolios through strategic acquisitions to gain access to new technologies and markets. The focus on minimally invasive procedures aligns with the broader healthcare trend towards less invasive treatments and improved patient outcomes. The gastrointestinal market is a multi-billion dollar market, and this acquisition positions Merit to capture a larger share of this market.

Comparison to Industry Standards

• The acquisition of a device focused on GERD treatment aligns with the industry's focus on addressing chronic conditions with minimally invasive solutions, similar to companies like Medtronic and Boston Scientific who have also invested in this area.
• The revenue contribution of $13 to $15 million for the remainder of 2024 is a significant addition for Merit's endoscopy segment, which is expected to grow 45% 51% year-over-year, compared to the industry average growth rate for medical device companies which is typically in the single to low double digits.
• The expectation of accretion to non-GAAP metrics in the first full year post-closing is a positive sign, as many acquisitions can be dilutive in the short term. This is similar to other successful acquisitions in the medical device space where companies have been able to quickly integrate and realize synergies.

Stakeholder Impact

• Shareholders may see a positive impact from the acquisition's long-term growth potential.
• Employees may experience changes due to the integration of the acquired business.
• Customers will have access to a broader range of products and solutions.
• Suppliers may see increased demand for their products and services.
• Creditors may see increased financial stability due to the acquisition.

Next Steps

• Merit will integrate the acquired assets and operations.
• Merit will discuss the acquisition and updated outlook for 2024 on their second quarter earnings report on August 1, 2024.
• Merit will file the Purchase Agreement with the SEC in a future filing.

Key Dates

Keywords

Merit Medical, EndoGastric Solutions, EsophyX Z+, GERD, gastroesophageal reflux disease, acquisition, endoscopy, medical devices, non-GAAP, financial guidance